Vir Biotechnology Stock Forecast
NASDAQ: VIRHealth CareBiotechnology: Biological Products (No Diagnostic Substances)USD
Market open · Delayed 15 min · as of Oct 9, 11:41 AM ET
VIR analyst consensus
Consensus (10 analysts)
strong_buy
Avg. price target
$20.78+78.22%
- Strong buy 3
- Buy 7
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
What analysts say
According to 10 Wall Street analysts covering Vir Biotechnology (2026-10-07), 10 rate the stock a buy or strong buy, 0 rate it a hold and 0 rate it a sell or strong sell, for a consensus rating of "strong_buy". The average 12-month price target is $20.78, with a high estimate of $30.00 and a low estimate of $15.00. The average target implies upside of 78.2% from the current price of $11.66.
The spread between the highest and lowest targets is 100.0%, a wide range that reflects significant disagreement among analysts. Price targets and ratings are the opinions of third-party analysts, not MetaCap. They are frequently revised and have a mixed track record, so treat them as one input among many for VIR.
Summary generated from market data by MetaCap's automated system. Methodology
Rating distribution
| Rating | Analysts | Share |
|---|---|---|
| Strong buy | 3 | 30% |
| Buy | 7 | 70% |
| Hold | 0 | 0% |
| Sell | 0 | 0% |
| Strong sell | 0 | 0% |
Ratings as of 2026-10-07.
Price target scenarios
| Target | Price | vs. current |
|---|---|---|
| Low target | $15.00 | +28.64% |
| Average target | $20.78 | +78.22% |
| High target | $30.00 | +157.29% |